DE60230029D1 - Immunisierungstherapie zur behandlung von atherosklerose - Google Patents

Immunisierungstherapie zur behandlung von atherosklerose

Info

Publication number
DE60230029D1
DE60230029D1 DE60230029T DE60230029T DE60230029D1 DE 60230029 D1 DE60230029 D1 DE 60230029D1 DE 60230029 T DE60230029 T DE 60230029T DE 60230029 T DE60230029 T DE 60230029T DE 60230029 D1 DE60230029 D1 DE 60230029D1
Authority
DE
Germany
Prior art keywords
treatment
atherosclerosis
immunization therapy
cardiovascular diseases
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60230029T
Other languages
English (en)
Inventor
Jan Nilsson
Prediman K Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forskarpatent I SYD AB
Cedars Sinai Medical Center
Original Assignee
Forskarpatent I SYD AB
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101232A external-priority patent/SE0101232D0/xx
Application filed by Forskarpatent I SYD AB, Cedars Sinai Medical Center filed Critical Forskarpatent I SYD AB
Application granted granted Critical
Publication of DE60230029D1 publication Critical patent/DE60230029D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE60230029T 2001-04-05 2002-04-05 Immunisierungstherapie zur behandlung von atherosklerose Expired - Lifetime DE60230029D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101232A SE0101232D0 (sv) 2001-04-05 2001-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density liprotein
SE0103754A SE0103754L (sv) 2001-04-05 2001-11-09 Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
PCT/SE2002/000679 WO2002080954A1 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein

Publications (1)

Publication Number Publication Date
DE60230029D1 true DE60230029D1 (de) 2009-01-08

Family

ID=26655437

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60230029T Expired - Lifetime DE60230029D1 (de) 2001-04-05 2002-04-05 Immunisierungstherapie zur behandlung von atherosklerose

Country Status (18)

Country Link
EP (42) EP2289925A1 (de)
JP (6) JP2004529143A (de)
CN (4) CN101486766A (de)
AT (2) ATE510851T1 (de)
AU (1) AU2002246484B8 (de)
BR (1) BR0208685A (de)
CA (3) CA2827167A1 (de)
CY (1) CY1108817T1 (de)
DE (1) DE60230029D1 (de)
DK (3) DK2295464T3 (de)
EE (2) EE200300487A (de)
ES (2) ES2317999T3 (de)
IL (4) IL158285A0 (de)
PL (4) PL215401B1 (de)
PT (1) PT1383526E (de)
RU (1) RU2296582C2 (de)
SE (1) SE0103754L (de)
WO (1) WO2002080954A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
IL161110A0 (en) 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
AU2003267905B2 (en) * 2002-10-04 2009-02-05 Biolnvent International Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302422D0 (sv) 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
SE0400683D0 (sv) * 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
CN1968965B (zh) 2004-04-15 2015-12-16 阿瑟拉生物技术公司 磷酸胆碱偶联物和相应抗体
EP1676602A1 (de) 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Kontinuierlicheverabreichung von Epitope aus dem atherosklerotischem Belag zur Behandlung von Atheriosklerose
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
WO2008080030A2 (en) * 2006-12-22 2008-07-03 Abbott Laboratories Cardiovascular autoimmune disease panel and methods of using same
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
EP2538222B1 (de) * 2007-11-05 2021-08-25 Nordic Bioscience A/S Biochemische Marker zur Bewertung des CVD-Risikos
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010018870A1 (ja) * 2008-08-15 2010-02-18 藤倉化成株式会社 動脈硬化診断用ポリペプチドマーカー、及び該マーカー等を用いる動脈硬化の検出方法、並びに動脈硬化診断用キット
AU2010319323B2 (en) 2009-11-14 2015-01-15 Cardiovax, Llc Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
WO2012024309A2 (en) 2010-08-18 2012-02-23 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
WO2012065135A2 (en) 2010-11-12 2012-05-18 Cedars-Sinai Medical Center Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100
AU2011325946A1 (en) 2010-11-12 2013-05-30 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
CA2817543A1 (en) * 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
EP2741770A4 (de) 2011-08-09 2014-12-31 Athera Biotechnologies Ab Antikörperbindung an phosphorylcholin (pc) und/oder pc-konjugate
AR087485A1 (es) 2011-08-09 2014-03-26 Athera Biotechnologies Ab Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
US10087234B2 (en) 2012-11-06 2018-10-02 Les Hopitaux Universitaires De Geneve Mimetic peptides
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN103860470A (zh) * 2014-03-05 2014-06-18 贵州中泰生物科技有限公司 一种口服高密度脂蛋白脂质体的制备方法
CN105315364B (zh) * 2014-06-17 2018-09-18 广州文瑞生物科技有限公司 胶原蛋白vi疫苗预防动脉粥样硬化
WO2016187250A1 (en) * 2015-05-19 2016-11-24 La Jolla Institute For Allergy And Immunology Human apob100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN108478817B (zh) * 2018-03-16 2020-10-27 北京大学 一种动脉粥样硬化检测试剂及其制备方法
CA3101767A1 (en) 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of psoriasis
CA3129373A1 (en) 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5972890A (en) 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
WO1993018067A1 (en) * 1992-03-06 1993-09-16 Abbott Laboratories Immunocapture assay for direct quantitation of specific lipoprotein cholesterol levels
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
EP0671926B1 (de) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunmodulierende peptide
KR0185334B1 (ko) 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6156315A (en) * 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
EP0911344B1 (de) * 1997-10-15 2004-03-03 Fujirebio Inc. Monoklonaler Antikörper gegen Apo B-48, Hybridoma, und Verfahren zur Verwendung
EP1062512A4 (de) * 1998-03-10 2001-12-12 Univ California Verfahren und hilfsmittel zum identifizieren von verbindungen, die atherosklerose modulieren indem sie ldl-proteoglykanbindungen beeinflussen
WO2000002920A1 (en) * 1998-07-13 2000-01-20 University Of Otago Inhibition of lipoprotein formation
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
ATE506615T1 (de) * 1999-10-26 2011-05-15 Univ California Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten
GB2373500B (en) * 2000-02-04 2004-12-15 Aeomica Inc Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
IL151355A0 (en) * 2000-03-03 2003-04-10 Smithkline Beecham Biolog Vaccine for the treatment of artherosclerosis
SE0000855D0 (sv) * 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
EP1186299A1 (de) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems
AU2002243382A1 (en) * 2000-10-25 2002-06-24 Vincent Agnello Method of inhibiting infection by HCV, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
AU2002241603A1 (en) * 2000-11-10 2002-06-03 University Of Utah Research Foundation Carrier system for specific artery wall gene delivery
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US7241861B2 (en) * 2001-05-15 2007-07-10 Japan Immunoresearch Laboratories Co., Ltd. High density lipoprotein-reactive peptides
EP1469887A4 (de) * 2001-07-20 2006-01-11 Eidgenoess Tech Hochschule Zusammensetzungen und verfahren zur verwendung als bioaktive mittel aus sulfatierten und sulfonierten aminosäuren

Also Published As

Publication number Publication date
EP1383526A1 (de) 2004-01-28
EP2295464A1 (de) 2011-03-16
CY1108817T1 (el) 2014-04-09
PL217858B1 (pl) 2014-08-29
JP2011063598A (ja) 2011-03-31
EP2147929A3 (de) 2010-04-14
IL195356A0 (en) 2009-08-03
EP2289934B1 (de) 2013-11-13
EP2289934A1 (de) 2011-03-02
ES2546293T3 (es) 2015-09-22
EP2289920A1 (de) 2011-03-02
AU2002246484A1 (en) 2002-10-21
EP2289925A1 (de) 2011-03-02
EP2289931A1 (de) 2011-03-02
EP2289916A1 (de) 2011-03-02
EE200700052A (et) 2008-08-15
EP2289933A1 (de) 2011-03-02
EP2147929A2 (de) 2010-01-27
DK1383526T3 (da) 2009-03-30
EP2289928A1 (de) 2011-03-02
JP2013144687A (ja) 2013-07-25
EP2305708A1 (de) 2011-04-06
CN101284874A (zh) 2008-10-15
IL158285A (en) 2009-12-24
EP2295458A1 (de) 2011-03-16
EP2147680A3 (de) 2010-04-14
EP2289922A1 (de) 2011-03-02
EP2147928A3 (de) 2010-04-14
EP2147928A2 (de) 2010-01-27
EE200300487A (et) 2004-02-16
JP2004529143A (ja) 2004-09-24
EP2147930A2 (de) 2010-01-27
AU2002246484B2 (en) 2007-04-19
EP2295459A1 (de) 2011-03-16
EP2295463A1 (de) 2011-03-16
CA2606839C (en) 2015-06-09
EP2295464B1 (de) 2015-06-03
CN1505525A (zh) 2004-06-16
PL215401B1 (pl) 2013-12-31
PL367301A1 (en) 2005-02-21
EP2147930A3 (de) 2010-04-14
EP2289918A1 (de) 2011-03-02
ATE415423T1 (de) 2008-12-15
EP2289923A1 (de) 2011-03-02
EP2289917A1 (de) 2011-03-02
EP2289926A1 (de) 2011-03-02
JP5270456B2 (ja) 2013-08-21
CA2443223A1 (en) 2002-10-17
BR0208685A (pt) 2004-03-30
CN103122031B (zh) 2015-07-22
PT1383526E (pt) 2009-02-27
IL188286A0 (en) 2008-03-20
DK2006301T3 (da) 2011-09-12
EP2006301A1 (de) 2008-12-24
EP2295457A1 (de) 2011-03-16
EP1918300A3 (de) 2009-06-17
JP5613890B2 (ja) 2014-10-29
CN103122031A (zh) 2013-05-29
EP2295460A1 (de) 2011-03-16
EP2289924A1 (de) 2011-03-02
EP2289919A1 (de) 2011-03-02
PL400308A1 (pl) 2012-12-17
EP2289912A1 (de) 2011-03-02
EP2289930A1 (de) 2011-03-02
EP2289927A1 (de) 2011-03-02
EP2289921A1 (de) 2011-03-02
CN1505525B (zh) 2012-11-07
EP2295461A1 (de) 2011-03-16
RU2003132443A (ru) 2005-02-27
EP2289914A1 (de) 2011-03-02
EP1918300A2 (de) 2008-05-07
EP2147680A2 (de) 2010-01-27
WO2002080954A1 (en) 2002-10-17
IL158285A0 (en) 2004-05-12
CA2606839A1 (en) 2002-10-17
JP2011068654A (ja) 2011-04-07
RU2296582C2 (ru) 2007-04-10
AU2002246484B8 (en) 2007-06-14
CN101486766A (zh) 2009-07-22
EP2289915A1 (de) 2011-03-02
JP2009191078A (ja) 2009-08-27
ATE510851T1 (de) 2011-06-15
JP5300819B2 (ja) 2013-09-25
DK2295464T3 (en) 2015-08-17
JP2008169215A (ja) 2008-07-24
EP2289935A1 (de) 2011-03-02
EP2295462A1 (de) 2011-03-16
SE0103754L (sv) 2002-10-06
EP1383526B1 (de) 2008-11-26
EP2289929A1 (de) 2011-03-02
CA2443223C (en) 2013-11-26
EP2289932A1 (de) 2011-03-02
EP2289913A1 (de) 2011-03-02
EP2295460B1 (de) 2015-06-03
SE0103754D0 (sv) 2001-11-09
JP5300820B2 (ja) 2013-09-25
CN101284874B (zh) 2012-10-03
CA2827167A1 (en) 2002-10-17
EP2305706A1 (de) 2011-04-06
ES2317999T3 (es) 2009-05-01
EP2006301B1 (de) 2011-05-25
EP2305707A1 (de) 2011-04-06

Similar Documents

Publication Publication Date Title
ATE415423T1 (de) Immunisierungstherapie zur behandlung von atherosklerose
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
AT500379B8 (de) Tau-proteine
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
ATE470676T1 (de) Anti-vegf-2 antikörper
HK1088909A1 (en) Peptide-based immunization therapy for treatment of atherosclerosis
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
BRPI0216049B8 (pt) "terapia de imunização à base de peptídeo para tratamento de arteriosclerose"

Legal Events

Date Code Title Description
8364 No opposition during term of opposition